NYSEAMERICAN:DXR

Daxor Stock Forecast, Price & News

$10.11

+0.03 (+0.30 %)

(As of 04/22/2021 01:27 PM ET)

Add

Compare

Today's Range

$10.11

Now: $10.11▼

$10.11

50-Day Range

$12.41

MA: $12.75▼

$13.20

52-Week Range

$9.76

Now: $10.11▼

$24.08

Volume100 shs

Average Volume10,151 shs

Market Capitalization$39.32 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.94

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:DXR

Previous SymbolNYSE:DXR

CUSIPN/A

CIK27367

Webwww.daxor.com

Phone+1-212-3308500

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares3,889,000

Market Cap$39.32 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Daxor Co. (NYSEAMERICAN:DXR) CEO Michael Richard Feldschuh Purchases 4,200 Shares
April 17, 2021 | americanbankingnews.com

Daxor (NYSEAMERICAN:DXR) Share Price Passes Below Two Hundred Day Moving Average of $13.87
April 8, 2021 | americanbankingnews.com

Daxor (NYSEAMERICAN:DXR) Stock Rating Reaffirmed by Ascendiant Capital Markets
March 31, 2021 | americanbankingnews.com

Daxor Biotech Blood Volume Innovation Is Rapidly Improving Patient Outcomes
March 25, 2021 | markets.businessinsider.com

DAXOR CORPORATION TO PARTICIPATE IN BENZINGA BIOTECH SMALL CAP CONFERENCE
March 18, 2021 | finance.yahoo.com

Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual Conference
March 16, 2021 | finance.yahoo.com

DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER
March 15, 2021 | finance.yahoo.com

Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
March 4, 2021 | finance.yahoo.com

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)
February 27, 2021 | finance.yahoo.com

Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
February 26, 2021 | finance.yahoo.com

DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
February 19, 2021 | finance.yahoo.com

DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
February 5, 2021 | finance.yahoo.com

New Research Demonstrates the Clinical Utility with Daxor’s Blood Volume Analyzer (BVA-100®) in Critical Care
February 4, 2021 | finance.yahoo.com

DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT
January 26, 2021 | finance.yahoo.com

DAXOR ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH L1 ENTERPRISES GOVERNMENT DISTRIBUTOR
January 13, 2021 | finance.yahoo.com

Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
January 8, 2021 | finance.yahoo.com

Daxor Corporation Announces Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
December 10, 2020 | finance.yahoo.com

Daxor Corporation to Present at the 13th Annual LD Micro Main Event 2020
December 9, 2020 | finance.yahoo.com

THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
November 19, 2020 | finance.yahoo.com

OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
October 29, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.72 out of 5 stars

Medical Sector

221st out of 2,024 stocks

Surgical & Medical Instruments Industry

22nd out of 169 stocks

3.5 Analyst's Opinion

Consensus Rating
Daxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.50, Daxor has a forecasted upside of 112.7% from its current price of $10.11.
Amount of Analyst Coverage
Daxor has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Daxor has received 155 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Daxor has received 139 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Daxor has received 52.72% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote “Outperform” if you believe DXR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Daxor does not currently pay a dividend.
Dividend Growth
Daxor does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Daxor insiders have bought more of their company's stock than they have sold. Specifically, they have bought $43,386.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
77.90% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.99% of the stock of Daxor is held by institutions.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$10.11

+0.03 (+0.30 %)

(As of 04/22/2021 01:27 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

Is Daxor a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Daxor stock.
View analyst ratings for Daxor or view top-rated stocks.

What stocks does MarketBeat like better than Daxor?

Wall Street analysts have given Daxor a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Daxor wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Daxor's stock price been impacted by Coronavirus?

Daxor's stock was trading at $9.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DXR stock has increased by 3.1% and is now trading at $10.11.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for DXR?

2 Wall Street analysts have issued 1-year price objectives for Daxor's shares. Their forecasts range from $21.00 to $22.00. On average, they anticipate Daxor's stock price to reach $21.50 in the next year. This suggests a possible upside of 112.7% from the stock's current price.
View analysts' price targets for Daxor or view top-rated stocks among Wall Street analysts.

Who are Daxor's key executives?

Daxor's management team includes the following people:

Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 52, Pay $100k)
Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 56, Pay $127.92k)
Mr. Robert J. Michel M.B.A., CPA, CPA, CFO, Chief Compliance Officer & Corp. Sec. (Age 64)
Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
Mr. Guido Manzo, VP of Sales

Who are some of Daxor's key competitors?

Some companies that are related to Daxor include Apollo Endosurgery (APEN), Lyra Therapeutics (LYRA), Repro Med Systems (KRMD), Brainsway (BWAY), Isoray (ISR), Liquidia (LQDA), Repro-Med Systems (REPR), Nemaura Medical (NMRD), Avinger (AVGR), Beyond Air (XAIR), Venus Concept (VERO), Spectral Medical (EDTXF), Pro-Dex (PDEX), LENSAR (LNSR) and SANUWAVE Health (SNWV).
View all of DXR's competitors.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), iBio (IBIO), (MRNA), Micron Technology (MU) and (SNY).

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $10.11.

How much money does Daxor make?

Daxor has a market capitalization of $39.32 million.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

Where are Daxor's headquarters?

Daxor is headquartered at 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500 or via email at [email protected]

This page was last updated on 4/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here